Hiromitsu Maekawa

1.1k citations
11 papers · 852 indexed · h-index 10

Hiromitsu Maekawa

11 papers receiving 835 citations

Peers

Hiromitsu Maekawa
Comparison fields: 5 of 78
  • Cardiology and Cardiovascular Medicine 275
  • Cancer Research 156
  • Cellular and Molecular Neuroscience 159
  • Oncology 183
  • Molecular Biology 458
Replace Frederic Pipp with:
Frederic Pipp Germany
M M Thompson United States
Curran Murphy United States
Youichi Katoh Japan
Jan‐Marcus Daniel Germany
Joshua P. Anderson United States
Kunio Morishige Japan
Kunio Yasunaga Japan
Yujung Kang South Korea
Josette Philippe France
Hiromitsu Maekawa relative to Frederic Pipp Germany Frederic Pipp's profile →
Citations per field
00.5×4.3×
Frederic Pipp · 1×
Citations per year

Countries citing papers authored by Hiromitsu Maekawa

Since Specialization
Citations

This map shows the geographic impact of Hiromitsu Maekawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiromitsu Maekawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiromitsu Maekawa more than expected).

Fields of papers citing papers by Hiromitsu Maekawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiromitsu Maekawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiromitsu Maekawa. The network helps show where Hiromitsu Maekawa may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Hiromitsu Maekawa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hiromitsu Maekawa Line = papers co-authored together Hiromitsu Maekawa links everyone, so they are left out of the graph.

All Works

11 of 11 papers shown
#Work
1 20232
2 200812
3 2005183
4 200531
5 2005187
6 200491
7 200378
8 200368
9 2003110
10 200230
11 199760

About Hiromitsu Maekawa

Hiromitsu Maekawa is a scholar working on Cellular and Molecular Neuroscience, Cardiology and Cardiovascular Medicine and Parasitology, having authored 11 papers that have together received 852 indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (7 papers), Lipid metabolism and disorders (3 papers), Axon Guidance and Neuronal Signaling (3 papers), Receptor Mechanisms and Signaling (2 papers), Apelin-related biomedical research (2 papers), Parasitic Diseases Research and Treatment (1 paper), Natural Compounds in Disease Treatment (1 paper) and Adipokines, Inflammation, and Metabolic Diseases (1 paper). The work is most often cited by research in Cardiology and Cardiovascular Medicine (275 citations), Cancer Research (156 citations) and Cellular and Molecular Neuroscience (159 citations). Hiromitsu Maekawa has collaborated with scholars based in Japan, South Korea and Finland. Frequent co-authors include Toshio Suda, Yuichi Oike, Tohru Morisada, Yasuhiro Ito, Takashi Urano, Yoshiaki Kubota, Masaki Akao, Kunio Yasunaga, Keishi Miyata and Yoshishige Kimura. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026